Weekly Low-Dose Docetaxel-Based Chemoradiotherapy for Locally Advanced Oropharyngeal or Hypopharyngeal Carcinoma: A Retrospective, Single-Institution Study

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 2, 2010, Pages 417-424

  Fukada, Junichi ^a   Shigematsu, Naoyuki ^a   Takeda, Atsuya ^b   Ohashi, Toshio ^a   Tomita, Toshiki ^a   Shiotani, Akihiro ^c   Kunieda, Etsuo ^a   Kawaguchi, Osamu ^a   Fujii, Masato ^a,d   Kubo, Atsushi ^a  

^a KEIO UNIVERSITY   (Japan)

^b Ofuna Chuo Hospital   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Concurrent chemoradiotherapy; Docetaxel; Hypopharyngeal carcinoma; Oropharyngeal carcinoma

Indexed keywords

5-FLUOROURACIL; ACTIVE AGENTS; ACUTE TOXICITY; CHEMORADIOTHERAPY; CIS-PLATIN; CONCURRENT CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DOCETAXEL; HEMATOLOGIC TOXICITY; HEMOGLOBIN LEVELS; KAPLAN-MEIER METHOD; LOCOREGIONAL CONTROL RATE; LOW DOSE; MUCOSITIS; MULTI VARIATE ANALYSIS; OPTIMAL PROTOCOLS; OROPHARYNGEAL; OVERALL SURVIVAL; PROGNOSTIC FACTORS; SIGNIFICANT FACTORS; UNIVARIATE;

CHEMOTHERAPY; DECISION MAKING; DISEASE CONTROL; PLATINUM COMPOUNDS; TOXICITY;

MULTIVARIANT ANALYSIS;

CISPLATIN; DOCETAXEL; FLUOROURACIL; HEMOGLOBIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPHARYNX CARCINOMA; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MUCOSITIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 73649134695     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.01.056     Document Type: Article

References (42)

1. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
2. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
3. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
4. Adelstein D.J., Lavertu P., Saxton J.P., et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88 (2000) 876-883
5. Marcial V.A., Pajak T.F., Mohiuddin M., et al. Concomitant cisplatin and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Cancer 66 (1990) 1861-1868
6. Al-Sarraf M., Pajak T.F., Byhardt W.B., et al. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37 (1997) 777-782
7. Dreyfuss A.L., Clark J.R., Norris C.M., et al. Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14 (1996) 1672-1678
8. Catimel G., Verweji J., Mattijssen V., et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5 (1994) 533-537
9. Ringel I., and Horwitz S.B. Studies with RP56976 (Taxotere): A semi synthetic analogue of Taxol. J Natl Cancer Inst 83 (1991) 288-291
10. Geuritte-Voegelein F., Guenard D., Lavalle F., et al. Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34 (1991) 992-998
11. Chaffey J.T., and Hellman S. Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Res 31 (1971) 1613-1615
12. Hennequin C., Giocanti N., and Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 56 (1996) 1842-1850
13. Fujii M., Tsukuda M., Satake B., et al. Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 9 (2004) 107-112
14. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
15. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355 (2000) 949-955
16. Bourhis J., Maitre A.L., Baujat B., et al. Individual patients' data meta-analysis in head and neck cancer. Curr Opin Oncol 19 (2007) 188-194
17. Budach W., Hehr T., Budach V., et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6 (2006) 28
18. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368 (2006) 843-854
19. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
20. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
21. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18 (2000) 1458-1464
22. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol 23 (2005) 1125-1135
23. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 (2006) 1072-1078
24. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
25. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
26. Bernier J., Domenge C., Oasahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
27. Tishler R.B., Norris Jr. C.M., Colevas A.D., et al. A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 95 (2002) 1472-1481
28. Suzuki M., Nishimura Y., Nakamatsu K., et al. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Jpn J Clin Oncol 33 (2003) 297-301
29. Calais G., Bardet E., Sire C., et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. Int J Radiat Oncol Biol Phys 58 (2004) 161-166
30. Tishler R.B., Posner M.R., Norris Jr. C.M., et al. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 65 (2006) 1036-1044
31. Hasse K., Heinrich B., Zimmermann F., et al. Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors. Strahlenther Onkol 176 (2000) 67-72
32. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
33. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695-1704
34. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171
35. Lee W.T., Akst L.M., Adelstein D.J., et al. Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. Head Neck 28 (2006) 808-812
36. Lee N., Puri D.R., Blanco A.I., et al. Intensity-modulated radiation therapy in head and neck cancers: An update. Head Neck 29 (2007) 387-400
37. Dubray B., Mosseri V., Brunin F., et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 201 (1996) 553-558
38. Lee W.R., Berkey B., Marcial V., et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol 42 (1998) 1069-1075
39. Schafer U., Micke O., Muller S.B., et al. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 8 (2003) 527-534
40. Redes M.D., Stoehr M., Kazic N., et al. Locally advanced stage IV squamous cell carcinoma of the head and neck: Impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 1108-1114
41. Becker A., Stadler P., Lavey R.S., et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol 46 (2000) 459-466
42. Nordsmark M., and Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 43 (2004) 396-403